Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07616687

Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

Crohn's disease (CD) is a chronic and destructive inflammatory disease of the gastrointestinal tract characterized by phases of relapse and remission. Tumor necrosis factor (TNF) antagonists, anti-integrins and anti-interleukin (IL) 12/23 are the main therapeutic agents to obtain deep remission and prevent disability. Despite the significant advances these biologics represent in treating inflammatory bowel disease (IBD), many patients experience suboptimal responses, including primary non-response or a loss of effectiveness over time, often leading to treatment discontinuation. For all these medications, a dose-response relationship has been demonstrated and an increase in dose or dosing frequency is recommended. Dose escalation is now an essential therapeutic approach necessary in 30 to 50% of CD patients treated with biologics. This strategy, supported by international guidelines, allows for long-term efficacy to be maintained without compromising safety.

Guselkumab (GUS) is a monoclonal antibody targeting the p19 subunit of IL-23. In a recent phase III trial (GALAXI), GUS demonstrated superiority of both subcutaneous (SC) maintenance doses (200 mg every 4 weeks [q4w] and 100 mg every 8 weeks [q8w]) compared to placebo and ustekinumab. In the GALAXI phase III program, at least 30% of patients did not achieve clinical response after a 12-week intravenous induction, and almost 20% experienced a loss of response by week 44. In these patients, the benefit of an intensified dose of GUS (200 mg q4w) maintenance remains to be determined to guide clinicians in optimizing its use in clinical practice. The investigator aimed to evaluate the one-year effectiveness of GUS in CD in real-world settings and under optimal conditions allowing dose intensification.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Crohn Disease (CD) Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intensification Intestinal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Chu Amiens Picardie

Amiens, 80054, France

Location status: Recruiting

About this study

Interventionnel, open multicenter study, the objectives are:

Primary Objective To evaluate the one-year effectiveness of GUS in CD in real-world setting.

Secondary Objectives

  • To evaluate the effectiveness of GUS intensification from 100 mg q8w to 200 mg q4w in patients with loss of response,
  • To evaluate the effectiveness of an intensified GUS 200 mg q4w maintenance therapy in patients who are primary non-responders to GUS SC induction at 12 weeks;
  • To assess the factors associated with GUS intensification effectiveness.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Patients with a diagnosis of CD according to ECCO guidelines,
  • 18 years of age or older at the time of informed consent,
  • Absence of contraindication to guselkumab,
  • Active disease according to PRO2 (abdominal pain > 1 or stool frequency > 3), and faecal calprotectin > 250 ug/g,
  • Objective active disease documented within ≤ 2 months by endoscopy or by MRI when not contraindicated, orby IUS),
  • Not currently participating in any interventional research.
  • Patient naïve or exposed to one or more advanced therapy, in accordance with the approved indication for guselkumab in Crohn's disease.
  • Females of childbearing potential must have a negative serum pregnancy test at the baseline Visit.

Exclusion criteria

  • - Patient under legal protection,
  • Previous exposure to an anti-IL23
  • Combination of advanced therapy with GUS,
  • Patient with ostomy,
  • Pregnant or breastfeeding woman,
  • Patient with perianal CD predominant disease.
  • Active clinically significant infection or HIV, Hep B, Hep C, or active tuberculosis

Treatment and study plan

Guselkumab

Drug

Guselkumab is a human monoclonal antibody targeting IL-23. In this study, patients receive guselkumab as part of a treat-to-target strategy. At week 12 (W12), patients are managed according to disease response: those with adequate response continue standard maintenance dosing, while non-responders are escalated to an intensified treatment regimen with adjusted dosing frequency.

Primary outcomes

  1. - Steroid free clinical remission (SFCR) associated with fecal calprotectin < 250 ug/g at Week 48

    Time frame: Week 48 +/- 12Weeks for the patients who are intensified between Week 32 and Week 48

    Steroid-free clinical remission (SFCR), defined as clinical remission measured by the patient reprt outcome, PRO2 : abdominal pain ≤ 1 and stool frequency ≤ 3, without corticosteroid use at the time of assessment, combined with fecal calprotectin < 250 µg/g.

  2. - Steroid free clinical remission (SFCR) associated with fecal calprotectin < 250 ug/g at Week 48

    Time frame: Week 48 (+/-12Weeks)

    Steroid free clinical remission measured by abdominal pain ≤ 1 and stool frequency ≤ 3 with feacal calprotection < 250 ug/g at Week 48

Secondary outcomes

  1. - Morphological remission at Week 48 assessed using the same tool that was used for the patient's inclusion: endoscopy, MRI or IUS (major secondary endpoint),

    Time frame: Week 48

    Evaluation of the morphological remission at W48 by one of the morphological exams: endoscopy: SES-CD <3 points, MRI: bowel wall thickness ≤3 mm without contrast enhancement, IUS: bowel wall thickness ≤3 mm without color doppler signal

  2. SFCR associated with fecal calprotectin < 250 ug/g at Week 12, Week 24 and Week 48,

    Time frame: Week 12, Week 24 and Week 48

    Evaluation of the clinical remission by PRO2: abdominal pain ≤ 1 and stool frequency ≤ 3, without corticoids associates with a biological remission defined by calprotectin < 250 ug/g

  3. Clinical remission at Week 12, Week 24 and Week 48

    Time frame: Week 12, Week 24 and Week 48

    Evaluation of the Clinical remission at the visits by the patient report outcome PRO2: abdominal pain ≤ 1 and stool frequency ≤ 3

  4. Biomarker remission at Week 12, Week 24 and Week 48

    Time frame: Week 12, Week 24 and Week 48,

    Evaluation of the biomarker remission: CRP < 5 g/L and fecal calprotectin <250 ug/g

  5. Need for GUS dose intensification (Week 12, Week 24 and Week 48)

    Time frame: Week 12, Week 24 and Week 48

    Evaluation of the need of intensification at the visits if the FC increase (> 25% with a minimal cut-off of 250 ug/g) between W12 and W48 or by a FC > 250 µg/g at W24, or disease activity confirmed by :

    Endoscopy: SES-CD > 3 points or IUS: bowel wall thickness ≥ 3 mm and/or with color doppler signal, or MRI : bowel wall thickness ≥3 mm and/or with contrast enhancement.

  6. Serum levels of guselkumab (Week 12, Week 24 and Week 48)

    Time frame: Week 12, Week 24 and Week 48

    Analysis of the serum level of guselkumab

  7. Neutralizing antibodies to guselkumab (Week 12, Week 24 and Week 48)

    Time frame: Week 12, Week 24 and Week 48

    Evaluation of the neutralization antibodies to guselkumab

  8. Crohn's Disease-related hospitalization during study period (Week 12, Week 24 and Week 48)

    Time frame: Week 12, Week 24 and Week 48

    Crohn's Disease-related hospitalization during study period

  9. -Change in the Short Inflammatory Bowel Disease Questionnaire(SIBD-Q) from baseline (Week 12, Week 24 and Week 48)

    Time frame: Week 12, Week 24 and Week 48

    Analysis of the change in SIBD-Q (quality of life index) during the study Score range: 10 - 70 The higher the score, the better the patient's clinical status (i.e., greater likelihood of remission).

  10. Guselkumab persistence

    Time frame: Week 48

    Evaluation of the Guselkumab persistence during the study

Study contacts

Contact information is provided by the study sponsor or research team.

MIRA RAAD

CONTACT

[email protected]

0033 6 85 29 97 64

Marie Coisnon

CONTACT

[email protected]

0033 6 08 95 94 11

Sponsors and collaborators

Lead sponsor

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Other

Registry information

Official study title

Optimal Care With Guselkumab In Crohn's Disease

Acronym: OPTIM

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jun 1, 2026
Registry last updated
Jun 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.